 PARSIPPANY, NJ, Oct. 15, 2021 GLOBE NEWSWIRE -- Interpace Biosciences, Inc. Interpace or the Company OTCQX: IDXG today announced that it, along with its subsidiaries, has entered into a new 7.5 Million revolving credit facility with Comerica Bank the Bank. The facility matures on September 30, 2023 and allows for advances based on 80 of eligible accounts receivable plus an applicable non-formula amount consisting of 2,000,000 of additional availability at close, stepping down 250,000 per quarter beginning with the quarter ending June 30, 2022. The interest rate is equal to prime plus .50, prime being the greater of the banks stated prime rate or the sum of the daily adjusting LIBOR rate, plus 2.5 per annum. The Bank will have a first priority security interest in substantially all of Interpaces and its subsidiaries assets and will be senior to the existing 7.5 Million bridge loans made by the Companys private equity investors. 